{
    "nctId": "NCT05831553",
    "briefTitle": "TIP in Patients Affected by Metastatic TNBC",
    "officialTitle": "Evaluation of a Tissue Immune Profile (TIP) in Patients Affected by Metastatic TNBC Treated With Upfront Atezolizumab Plus Nab-paclitaxel (TIP)",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Triple-negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients able and willing to provide a written informed consent to participate to the study;\n* Histological confirmed diagnosis of PD-L1 positive TNBC (\\> 1%)\n* Confirmed radiological or histological diagnosis of metastatic TNBC\n* Availability of tumor specimen in order to perform the requested analysis\n* Patients eligible for or treated with atezolizumab plus nab-paclitaxel first line as requested for clinical practice\n* Availability of complete clinical data on duration, efficacy and safety of the treatment\n\nExclusion Criteria:\n\n* Sample not sufficient to perform the requested tissue analysis\n* Patients unable to provide informed consent or with possible poor compliance with protocol procedures\n* Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;\n* Patients treated with the following drugs, because of the risk of immunosuppression: Chronic or high-dose oral corticosteroid therapy, TNF-inhibitors and Anti-T cell antibodies\n* Patients participating in other clinical studies.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}